| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Sisunatovir - (REVIRAL1) | Respiratory syncytial virus (RSV) infections in infants | Phase 2 | Oral | Respiratory | |
| Pfizer Inc. | Tisotumab vedotin - (innovaTV 207) | Squamous cell carcinoma of the head and neck (SCCHN) | Phase 2 | Data Released | Intravenous | Oncology |
| Pfizer Inc. | SPR206 | Multi-drug resistant (MDR) Gram-negative bacterial infections (renal impairment trial) | Phase 2 | Trial Discontinued | Intravenous | Antibiotic |
| Pfizer Inc. | PTemanogrel | Coronary Microvascular Obstruction (cMVO) | Phase 2 | Oral | Cardiology | |
| Pfizer Inc. | PTemanogrel | Coronary Microvascular Obstruction (cMVO) | Phase 2 | Oral | Cardiology | |
| Pfizer Inc. | APD418 | Acute heart failure (AHF) | Phase 2 | Intravenous | Cardiology | |
| Pfizer Inc. | Etrasimod | Alopecia areata (AA) | Phase 2 | Oral | Immunology | |
| Pfizer Inc. | Darovasertib (IDE196), MEKTOVI (​binimetinib) and Crizotinib | Metastatic uveal melanoma (MUM) | Phase 2 | Data Released | Oral | Oncology |